Patents by Inventor Andreas WERNITZNIG

Andreas WERNITZNIG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BINDING MOLECULES FOR THE TREATMENT OF CANCER
    Publication number: 20240150480
    Abstract: This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.
    Type: Application
    Filed: November 14, 2023
    Publication date: May 9, 2024
    Inventors: Klaus-Peter KUENKELE, Timothy FENN, Juan Manuel GARCIA-MARTINEZ, Jason HO, Christian KOESSL, Saurabh SEN, Vladimir VOYNOV, Andreas WERNITZNIG, Ertan ERYILMAZ, Rajkumar GANESAN, Abdulsalam SHAABAN
  • BINDING MOLECULES FOR THE TREATMENT OF CANCER
    Publication number: 20240052065
    Abstract: The present invention relates to novel binding molecules. The invention specifically relates to binding molecules that bind to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-3 (CDH3). The invention also relates to nucleic acids encoding such binding molecules; to methods for preparing such binding molecules; to host cells expressing or capable of expressing such binding molecules; to compositions comprising such binding molecules; and to uses of such binding molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Application
    Filed: July 13, 2023
    Publication date: February 15, 2024
    Inventors: Juan Manuel GARCIA-MARTINEZ, Stephan GLASER, Gale Lee HANSEN, Srinath KASTURIRANGAN, Klaus-Peter KUENKELE, Vladimir H. VOYNOV, Andreas WERNITZNIG, Chao ZHENG
  • TRAILR2 CDH17 binding molecules for the treatment of cancer
    Patent number: 11851495
    Abstract: This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: December 26, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus-Peter Kuenkele, Timothy Fenn, Juan Manuel Garcia-Martinez, Jason Ho, Christian Koessl, Saurabh Sen, Vladimir Voynov, Andreas Wernitznig
  • Novel Tri-specific Binding Molecules
    Publication number: 20220411533
    Abstract: The present invention relates to novel tri-specific binding molecules. The invention also relates to nucleic acids encoding such binding molecules; to methods for preparing such binding molecules; to host cells expressing or capable of expressing such binding molecules; to compositions comprising such binding molecules; and to uses of such binding molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Application
    Filed: June 15, 2022
    Publication date: December 29, 2022
    Inventors: Paul ADAM, Stephen R. COMEAU, Philip Nicholas GORMAN, Pankaj Gupta, Priyanka GUPTA, Karl-Heinz HEIDER, Srinath KASTURIRANGAN, Renate KONOPITZKY, Klaus-Peter KUENKELE, Sandeep KUMAR, Taneisha Ann-Tanara MACK, Elinborg Katrin OSTERMANN, Abdulsalam SHAABAN, David WEISMANN, Andreas WERNITZNIG, David S. YOUNG
  • BINDING MOLECULES FOR THE TREATMENT OF CANCER
    Publication number: 20210095038
    Abstract: This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.
    Type: Application
    Filed: October 30, 2020
    Publication date: April 1, 2021
    Inventors: Klaus-Peter KUENKELE, Timothy FENN, Juan Manuel GARCIA-MARTINEZ, Jason HO, Christian KOESSL, Saurabh SEN, Vladimir VOYNOV, Andreas WERNITZNIG, Ertan ERYILMAZ, Rajkumar GANESAN, Abdulsalam SHAABAN
  • TRAILR2 CDH17 binding molecules for the treatment of cancer
    Patent number: 10858438
    Abstract: This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: December 8, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus-Peter Kuenkele, Timothy Fenn, Juan Manuel Garcia-Martinez, Jason Ho, Christian Koessl, Saurabh Sen, Vladimir Voynov, Andreas Wernitznig
  • BINDING MOLECULES FOR THE TREATMENT OF CANCER
    Publication number: 20180179287
    Abstract: This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.
    Type: Application
    Filed: December 21, 2017
    Publication date: June 28, 2018
    Inventors: Klaus-Peter KUENKELE, Timothy FENN, Juan Manuel GARCIA-MARTINEZ, Jason HO, Christian KOESSL, Saurabh SEN, Vladimir VOYNOV, Andreas WERNITZNIG